ArticleIntegrative cancer therapies

JI017 Sensitizes EGFR-T790M NSCLC to Erlotinib by Extinguishing the STAT3-Survivin Axis.

Daeun Kim et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.